Photoeruption in a patient treated with capecitabine (Xeloda) for metastatic breast cancer [2]

Journal of the American Academy of Dermatology

Volumn 47, Issue 3, 2002, Pages 453-

  Willey, Andrea ^a   Glusac, Earl J ^a   Bolognia, Jean L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; LORATADINE; SUNSCREEN; TEGAFUR; ULOBETASOL PROPIONATE;

ADULT; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; DERMATITIS; DRUG INDUCED DISEASE; FEMALE; HUMAN; LETTER; METASTASIS; NAIL DISEASE; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PRURITUS; RASH; SKIN TOXICITY; XEROSIS;

EID: 0036737742     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.122745a     Document Type: Letter

References (5)

1. Roche Laboratories Inc. Xeloda (capecitabine) prescribing information. U.S.A. 1998.
2. Macdonald J. Oral fluoropyrimidines: a closer look at their toxicities. Am J Clin Oncol 1999;22:475-80.
3. Blum J, Jones S, Buzdar A, LoRusso P, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;2:485-93.
4. Cassidy J, Dirix L, Bissett D, Reigner B, Griffin T, Allman D, et al. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998;4:2755-61.
5. Horio T, Yokoyama M. Tegaful photosensitivity: lichenoid and eczematous types. Photodermatology 1986;3:192-3.